IRIS UniCatt

Evoli Stampanoni-B, Amelia
 Distribuzione geografica
Salva come PNG Salva come JPEG
Continente #
NA - Nord America 5.709
EU - Europa 4.244
AS - Asia 3.810
SA - Sud America 926
AF - Africa 120
OC - Oceania 20
Continente sconosciuto - Info sul continente non disponibili 10
Totale 14.839
Salva come PNG Salva come JPEG
Nazione #
US - Stati Uniti d'America 5.565
SG - Singapore 1.739
DE - Germania 1.179
CN - Cina 1.123
SE - Svezia 742
BR - Brasile 732
IT - Italia 434
UA - Ucraina 430
FR - Francia 286
IE - Irlanda 227
GB - Regno Unito 224
PL - Polonia 206
VN - Vietnam 183
IN - India 162
FI - Finlandia 146
ID - Indonesia 145
RU - Federazione Russa 121
TR - Turchia 78
CA - Canada 69
HK - Hong Kong 68
JP - Giappone 60
BD - Bangladesh 57
AR - Argentina 55
BE - Belgio 46
EC - Ecuador 44
MX - Messico 43
ES - Italia 38
IQ - Iraq 38
CI - Costa d'Avorio 34
NL - Olanda 34
CL - Cile 27
AT - Austria 26
ZA - Sudafrica 23
RO - Romania 22
PK - Pakistan 21
IL - Israele 19
VE - Venezuela 19
AU - Australia 18
CO - Colombia 17
KE - Kenya 16
PE - Perù 14
UZ - Uzbekistan 14
KR - Corea 13
LT - Lituania 12
CH - Svizzera 11
AE - Emirati Arabi Uniti 10
BG - Bulgaria 10
MA - Marocco 10
PY - Paraguay 10
SA - Arabia Saudita 10
EG - Egitto 9
JO - Giordania 9
AZ - Azerbaigian 8
OM - Oman 8
TN - Tunisia 8
CZ - Repubblica Ceca 7
IR - Iran 7
BZ - Belize 6
GR - Grecia 6
PT - Portogallo 6
A2 - ???statistics.table.value.countryCode.A2??? 5
DZ - Algeria 5
KZ - Kazakistan 5
PR - Porto Rico 5
CR - Costa Rica 4
DK - Danimarca 4
EU - Europa 4
HN - Honduras 4
LK - Sri Lanka 4
LU - Lussemburgo 4
NO - Norvegia 4
PA - Panama 4
TH - Thailandia 4
UY - Uruguay 4
AL - Albania 3
BO - Bolivia 3
BY - Bielorussia 3
ET - Etiopia 3
GA - Gabon 3
HU - Ungheria 3
KG - Kirghizistan 3
KH - Cambogia 3
LV - Lettonia 3
MY - Malesia 3
NI - Nicaragua 3
PH - Filippine 3
AO - Angola 2
CY - Cipro 2
DO - Repubblica Dominicana 2
JM - Giamaica 2
LB - Libano 2
MD - Moldavia 2
MU - Mauritius 2
NP - Nepal 2
NZ - Nuova Zelanda 2
PS - Palestinian Territory 2
A1 - Anonimo 1
BA - Bosnia-Erzegovina 1
BB - Barbados 1
BF - Burkina Faso 1
Totale 14.824
Salva come PNG Salva come JPEG
Città #
Chandler 891
Singapore 766
Ashburn 598
Jacksonville 285
Beijing 233
San Mateo 230
Dublin 217
New York 182
Warsaw 170
Wilmington 155
Ann Arbor 154
Nanjing 141
Jakarta 133
Houston 131
Los Angeles 122
Dearborn 116
Woodbridge 114
Boston 104
Cattolica 96
Chicago 81
Hefei 79
Dallas 76
Princeton 71
Milan 69
Redwood City 69
Hong Kong 65
Moscow 65
São Paulo 63
Lawrence 61
Ho Chi Minh City 58
Frankfurt am Main 57
North Bergen 56
Nürnberg 53
Seattle 51
Munich 50
Fairfield 49
Marseille 49
Bremen 46
Buffalo 46
Hanoi 45
Izmir 45
Nanchang 45
Rome 43
Fuzhou 42
Hangzhou 39
London 39
Brussels 38
Redmond 37
Abidjan 34
Tokyo 34
Nuremberg 33
Shanghai 32
Santa Clara 31
Mountain View 30
Tianjin 30
Shenyang 27
Norwalk 25
Boardman 24
Hebei 24
Zhengzhou 24
Changsha 23
Düsseldorf 23
Helsinki 23
Turku 23
Brooklyn 21
Porto Alegre 20
Belo Horizonte 18
Chennai 18
Kunming 18
Orem 18
Rio de Janeiro 18
Denver 17
Kent 17
Fortaleza 16
Leawood 16
Montreal 16
Poplar 16
San Francisco 16
Des Moines 15
Jiaxing 15
Millbury 15
Pune 15
Stockholm 15
Cambridge 14
Dhaka 14
Guayaquil 14
Nairobi 14
New Delhi 14
San Jose 14
Tashkent 14
University Park 14
Washington 14
Brasília 13
Mexico City 13
Toronto 13
Wroclaw 13
Amsterdam 12
Atlanta 12
Campinas 12
Guangzhou 12
Totale 7.411
Salva come PNG Salva come JPEG
Nome #
International consensus guidance for management of myasthenia gravis: Executive summary 230
Single-centre 40-year results of redo operation for recurrent thymomas. 227
Myasthenia gravis 223
Thirty-five-year follow-up analysis of clinical and pathologic outcomes of thymoma surgery. 213
T cell repertoire in DQ5-positive MuSK-positive myasthenia gravis patients 185
Distinctive clinical and neuroimaging characteristics of longitudinally extensive transverse myelitis associated with aquaporin-4 autoantibodies 185
Novel prognostic groups in thymic epithelial tumors: assessment of risk and therapeutic strategy selection. 184
Thymopoiesis, regulatory T cells, and TCRVbeta expression in thymoma with and without myasthenia gravis, and modulatory effects of steroid therapy 182
Hypoglossal palsy and coeliac disease: an uncommon presentation for a common disease? 179
Thymoma in patients with MG: characteristics and long-term outcome 177
Poly-autoimmunity in patients with myasthenia gravis: A single-center experience 173
Overcoming challenges in the diagnosis and treatment of myasthenia gravis 171
When myasthenia gravis is not all. 170
PTPN22 and myasthenia gravis: replication in an Italian population and meta-analysis of literature data 168
Flow Cytofluorimetric Analysis of Anti-LRP4 (LDL Receptor-Related Protein 4) Autoantibodies in Italian Patients with Myasthenia Gravis 166
A Genome-wide Association Study of Myasthenia Gravis 165
Overcoming challenges in the diagnosis and treatment of myasthenia gravis 164
Thymectomy in myasthenia gravis: proposal for a predictive score of postoperative myasthenic crisis. 162
Remission of myasthenia gravis with MuSK antibodies during ruxolitinib treatment 162
SFEMG: A piece in the diagnostic puzzle of myasthenia 160
Epidemiology, diagnostics, and biomarkers of autoimmune neuromuscular junction disorders 156
Long-Lasting Rituximab-Induced Reduction of Specific—But Not Total—IgG4 in MuSK-Positive Myasthenia Gravis 151
Efficacy and safety of rituximab for myasthenia gravis: a systematic review and meta-analysis 148
Human Leukocyte Antigen Class II associations in late-onset Myasthenia Gravis 148
3,4-Diaminopyridine may improve myasthenia gravis with MuSK antibodies 147
An Italian Neurology Outpatient Clinic Facing SARS-CoV-2 Pandemic: Data From 2,167 Patients 145
A b3 type-thymoma in a 7-year-old child with myasthenia gravis 141
Safety and efficacy of eculizumab in anti-acetylcholine receptor antibody-positive refractory generalised myasthenia gravis (REGAIN): a phase 3, randomised, double-blind, placebo-controlled, multicentre study 141
Myasthenia gravis with antibodies to MuSK: an update 137
Characterization of B cells in muscle-specific kinase antibody myasthenia gravis 136
Serological Immunoglobulin-Free Light Chain Profile in Myasthenia Gravis Patients 135
Anti-AChR-negative myasthenia gravis: clinical and immunological features 133
Response to therapy in myasthenia gravis with anti-MuSK antibody 131
HLA class II allele analysis in MuSK-positive myasthenia gravis suggests a role for DQ5. 130
Clinical characteristics and outcome of patients with autoimmune encephalitis: clues for paraneoplastic etiology 129
BAFF serum levels in myasthenia gravis: effects of therapy 125
Anti-MuSK antibody myasthenia gravis: clinical findings and response to treatment in two large cohorts. 125
Multiple paraneoplastic diseases associated with thymoma. 124
Thymectomy in myasthenia gravis via original video-assisted infra-mammary cosmetic incision and median sternotomy: long-term results in 180 patients. 124
Anti-acetylcholinesterase antibodies associate with ocular myasthenia gravis. 124
Pattern of ocular involvement in myasthenia gravis with MuSK antibodies 124
Acetylcholine receptor antibody positivity rate in ocular myasthenia gravis: a matter of age? 124
Determinants of cognitive impairment in elderly myasthenia gravis patients 122
Efficacy and safety of rituximab therapy in neuromyelitis optica spectrum disorders: A systematic review and meta-analysis 121
Disease specific enrichment of circulating let-7 family microRNA in MuSK+ myasthenia gravis 120
Diagnostic features and subtyping of thymoma lymph node metastases 119
Myasthenia gravis with presynaptic neurophysiological signs: Two case reports and literature review 119
Prognostic grading after complete resection for thymic malignancies 118
Overcoming challenges in the diagnosis and treatment of myasthenia gravis 116
Clinical and immunological characteristics of the spectrum of GFAP autoimmunity: a case series of 22 patients 116
Clinical features and outcome of patients with autoimmune cerebellar ataxia evaluated with the Scale for the Assessment and Rating of Ataxia 114
Management challenges in muscle-specific tyrosine kinase myasthenia gravis. 113
An Italian Neurology Outpatient Clinic Facing SARS-CoV-2 Pandemic: Data From 2,167 Patients 112
The difficulty in confirming clinical diagnosis of Myasthenia Gravis in a seronegative patient: a possible neurophysiological approach 112
Thymectomy in myasthenia gravis via original video-assisted infra-mammary cosmetic incision and median sternotomy: long term results in 180 patients. 112
Rituximab in myasthenia gravis: a "to be or not to be" inhibitor of T cell function 112
Comment on "Cutting edge: human CD4-CD8- thymocytes express FOXP3 in the absence of a TCR". 110
Clinical heterogeneity of seronegative myasthenia gravis 109
Ocular palsies in the absence of other neurological or ocular symptoms: analysis of 105 cases 107
Immunosuppressive therapies in myasthenia gravis 105
Reliability of SFEMG in diagnosing myasthenia gravis: Sensitivity and specificity calculated on 100 prospective cases. 105
Lower motor neuron involvement in longitudinally extensive transverse myelitis with and without aquaporin-4 antibodies 104
Thymic epithelial tumors express vascular endothelial growth factors and their receptors as potential targets of antiangiogenic therapy: a tissue micro array-based multicenter study 102
Epidemiological evidence for a hereditary contribution to myasthenia gravis: A retrospective cohort study of patients from North America 102
Guidelines for treatment of autoimmune neuromuscular transmission disorders. 101
Tumour necrosis factor beta gene polymorphisms in myasthenia gravis 100
The detection of neural autoantibodies in patients with antiepileptic-drug-resistant epilepsy predicts response to immunotherapy 99
Spontaneous recovery from anti-NMDAR encephalitis 98
In sickness and in health: when myasthenia gravis is a conjugal matter 98
Identification of genetic risk loci and prioritization of genes and pathways for myasthenia gravis: A genome-wide association study 98
Italian recommendations for Lambert-Eaton myasthenic syndrome (LEMS) management. 97
Acquired myasthenia gravis in childhood. 96
Molecular genetic alterations in egfr CA-SSR-1 microsatellite and egfr copy number changes are associated with aggressiveness in thymoma 94
Imatinib mesylate in thymic epithelial malignancies. 93
Thymoma recurrences in myasthenia gravis patients 92
IL-1 genes in myasthenia gravis: IL-1A -889 polymorphism associated with sex and age of disease onset 92
Thymectomy in the treatment of myasthenia gravis: report of 247 patients 91
EFNS/ENS Guidelines for the treatment of ocular myasthenia. 91
International Consensus Guidance for Management of Myasthenia Gravis: 2020 Update 91
Benefit and danger from immunotherapy in myasthenia gravis 89
Risk of cancer in patients with myasthenia gravis 88
Course and treatment of myasthenia gravis during pregnancy 88
Antibody-phenotype correlation in stiff-person syndrome 88
Early-onset myasthenia gravis: clinical characteristics and response to therapy 88
Clinical correlates with anti-MuSK antibodies in generalized seronegative myasthenia gravis 88
Randomized phase 2 study of FcRn antagonist efgartigimod in generalized myasthenia gravis. 87
Anti-MuSK antibodies: Correlation with myasthenia gravis severity 87
Safety and tolerability of SARS-Cov-2 vaccination in patients with myasthenia gravis: A multicenter experience 87
A practical guide to the recognition and management of myasthenia gravis 86
Neurophysiological challenges in myasthenia gravis associated with MuSK antibodies: a case report 86
SHP2 inhibitor protects AChRs from effects of myasthenia gravis MuSK antibody 85
Myasthenia gravis during interferon alfa therapy 84
Positive response to therapy in a patient with a seropositive paraneoplastic cerebellar degeneration and an endometrioid carcinoma of the vesicovaginal septum 84
Anti-P110 autoantibodies identify a subtype of "seronegative" myasthenia gravis with prominent oculobulbar involvement 83
Minimal manifestation status and prednisone withdrawal in the MGTX trial 83
Familial autoimmune myasthenia gravis with different pathogenetic antibodies 82
Post-intervention Status in Patients With Refractory Myasthenia Gravis Treated With Eculizumab During REGAIN and Its Open-Label Extension 81
Myasthenia gravis and associated autoimmune diseases 81
Identification of disease-specific autoantibodies in seronegative myasthenia gravis 81
Changes in regulatory T cells after rituximab in two patients with refractory myasthenia gravis. 80
Totale 12.311
Salva come PNG Salva come JPEG
Categoria #
all - tutte 61.924
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 61.924
Salva come PNG Salva come JPEG


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2020/2021563 0 0 0 0 0 50 135 28 121 52 143 34
2021/20221.290 111 97 32 69 97 45 34 197 62 78 182 286
2022/20232.629 313 361 205 387 155 311 256 217 273 41 70 40
2023/20241.174 53 318 47 84 46 163 86 74 11 27 132 133
2024/20252.252 54 90 181 60 171 66 72 119 376 172 455 436
2025/20263.539 954 176 358 805 1.149 97 0 0 0 0 0 0
Totale 15.016